$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000143853318000032 Filed on November 01, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$43.77M	$40.71M	$42.00K
YoY Change	104116.67%	101665.0%	-99.89%
Cost Of Revenue	$1.600M	$1.133M	$1.170M
YoY Change	36.75%	22.49%	-2.5%
Gross Profit	$42.17M	$39.57M	$41.00M
YoY Change	2.85%	-4571.53%	13.51%
Gross Profit Margin	96.34%	97.22%	97619.05%
Selling, General & Admin	$21.54M	$26.11M	$22.40M
YoY Change	-3.84%	5.05%	-0.8%
% of Gross Profit	51.08%	65.97%	54.63%
Research & Development	$31.70M	$32.45M	$19.49M
YoY Change	62.65%	65.47%	-2.55%
% of Gross Profit	75.17%	82.0%	47.54%
Depreciation & Amortization	$4.880M	$4.800M	$4.460M
YoY Change	9.42%	3.9%	6.44%
% of Gross Profit	11.57%	12.13%	10.88%
Operating Expenses	$48.76M	$76.29M	$57.35M
YoY Change	-14.99%	49.74%	3.25%
Operating Profit	-$4.985M	-$35.58M	-$15.18M
YoY Change	-67.15%	235.44%	-16.71%
Interest Expense	-$2.370M	-$2.533M	-$4.230M
YoY Change	-43.97%	283.79%	227.91%
% of Operating Profit
Other Income/Expense, Net	-$2.470M	-$18.52M	$4.139M
YoY Change	-159.68%	120.22%	-169.74%
Pretax Income	-$7.455M	-$54.10M	-$11.04M
YoY Change	-32.46%	184.49%	-10.17%
Income Tax	$0.00	$415.0K	$6.580M
% Of Pretax Income
Net Earnings	-$7.455M	-$54.52M	-$17.62M
YoY Change	-57.69%	206.37%	104.79%
Net Earnings / Revenue	-17.03%	-133.93%	-41947.62%
Basic Earnings Per Share	-$0.18	-$1.34	-$0.45
Diluted Earnings Per Share	-$0.18	-$1.34	-$0.55
COMMON SHARES
Basic Shares Outstanding	41.25M shares	40.43M shares	39.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$311.3M	$350.9M	$222.7M
YoY Change	39.83%	15.47%	-12.98%
Cash & Equivalents	$102.9M	$154.8M	$99.39M
Short-Term Investments	$208.5M	$196.1M	$123.3M
Other Short-Term Assets	$5.900M	$5.600M	$6.000M
YoY Change	-1.67%	115.38%	-27.71%
Inventory	$5.619M	$5.129M	$5.351M
Prepaid Expenses
Receivables	$12.66M	$13.45M	$13.87M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$495.7M	$503.0M	$325.8M
YoY Change	52.14%	54.6%	-1.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.146M	$3.323M	$3.230M
YoY Change	-2.6%	22.3%	24.86%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$186.7M		$184.8M
YoY Change	1.01%		1.52%
Long-Term Investments	$15.00M	$15.00M	$0.00
YoY Change
Other Assets	$7.709M	$7.393M	$5.556M
YoY Change	38.75%	4.11%	-24.55%
Total Long-Term Assets	$213.5M	$213.2M	$194.5M
YoY Change	9.74%	9.24%	0.83%
TOTAL ASSETS
Total Short-Term Assets	$495.7M	$503.0M	$325.8M
Total Long-Term Assets	$213.5M	$213.2M	$194.5M
Total Assets	$709.2M	$716.2M	$520.3M
YoY Change	36.29%	37.59%	-0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.954M	$9.314M	$18.94M
YoY Change	-63.28%	26.38%	151.77%
Accrued Expenses	$49.70M	$43.35M	$36.02M
YoY Change	37.97%	34.4%	8.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$22.50M	$22.40M
YoY Change
Total Short-Term Liabilities	$104.6M	$99.87M	$85.67M
YoY Change	22.12%	19.03%	2.89%
LONG-TERM LIABILITIES
Long-Term Debt	$195.1M	$192.8M	$45.10M
YoY Change	332.59%	329.4%	1.58%
Other Long-Term Liabilities	$17.55M	$4.885M	$2.472M
YoY Change	609.75%	28.28%	-38.35%
Total Long-Term Liabilities	$17.55M	$4.885M	$2.472M
YoY Change	609.75%	28.28%	-38.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.6M	$99.87M	$85.67M
Total Long-Term Liabilities	$17.55M	$4.885M	$2.472M
Total Liabilities	$390.9M	$397.1M	$227.2M
YoY Change	72.05%	83.86%	4.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.0M	-$262.6M	-$177.7M
YoY Change	51.99%	64.06%	57.14%
Common Stock	$589.8M	$582.7M	$471.8M
YoY Change	25.01%	25.27%	11.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$318.3M	$319.1M	$293.1M
YoY Change
Total Liabilities & Shareholders Equity	$709.2M	$716.2M	$520.3M
YoY Change	36.29%	37.59%	-0.94%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$7.455M	-$54.52M	-$17.62M
YoY Change	-57.69%	206.37%	104.79%
Depreciation, Depletion And Amortization	$4.880M	$4.800M	$4.460M
YoY Change	9.42%	3.9%	6.44%
Cash From Operating Activities	-$3.570M	-$3.900M	-$860.0K
YoY Change	315.12%	-162.9%	-89.87%
INVESTING ACTIVITIES
Capital Expenditures	-$3.860M	-$3.850M	-$2.940M
YoY Change	31.29%	2.94%	-30.5%
Acquisitions
YoY Change
Other Investing Activities	-$44.94M	-$157.7M	$2.840M
YoY Change	-1682.39%	-10340.26%	-91.82%
Cash From Investing Activities	-$48.80M	-$161.6M	-$110.0K
YoY Change	44263.64%	7310.55%	-100.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.0K	231.0M	1.370M
YoY Change	-62.04%	3861.58%	-127.13%
NET CHANGE
Cash From Operating Activities	-3.570M	-3.900M	-860.0K
Cash From Investing Activities	-48.80M	-161.6M	-110.0K
Cash From Financing Activities	520.0K	231.0M	1.370M
Net Change In Cash	-51.85M	65.51M	400.0K
YoY Change	-13062.5%	565.08%	-97.64%
FREE CASH FLOW
Cash From Operating Activities	-$3.570M	-$3.900M	-$860.0K
Capital Expenditures	-$3.860M	-$3.850M	-$2.940M
Free Cash Flow	$290.0K	-$50.00K	$2.080M
YoY Change	-86.06%	-100.5%	-148.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
	rtrx	Provision For Inventory ProvisionForInventory	-252000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	8842000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	8820000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41247609	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Trading Symbol TradingSymbol	rtrx
CY2017Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1523000	USD
CY2018Q3	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	2465000	USD
CY2017Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6989000	USD
CY2018Q3	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	11969000	USD
CY2017Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3896000	USD
CY2018Q3	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2913000	USD
CY2017Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13095000	USD
CY2018Q3	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	12611000	USD
CY2017Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6429000	USD
CY2018Q3	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6332000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9100000	USD
CY2018Q3	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19000000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	80900000	USD
CY2018Q3	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	87000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity	0.8
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash	0.2
CY2018Q1	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Weighted Average Ten Day Share Price Which Requires All Cash Payment BusinessCombinationOptionAgreementWeightedAverageTenDaySharePriceWhichRequiresAllCashPayment	19.26
CY2017Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4400000	USD
CY2017Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4429000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	11100000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	11057000	USD
CY2018Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	16600000	USD
CY2018Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	16601000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	22400000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	22387000	USD
CY2018Q3	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	532830	shares
	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	956887	shares
	rtrx	Debt Conversion Equity DebtConversionEquity	77400000	USD
CY2018Q3	rtrx	Debt Conversion Liability DebtConversionLiability	198600000	USD
CY2018Q3	rtrx	Debt Instrument Convertible Note Market Price Per1000 DebtInstrumentConvertibleNoteMarketPricePer1000	1027	USD
CY2018Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	USD
CY2018Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	4000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	123574000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	302000	USD
CY2018Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	249000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2018Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	559000	USD
CY2017Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	424000	USD
CY2018Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	196623000	USD
CY2017Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	78388000	USD
CY2018Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	128174000	USD
CY2017Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	5883000	USD
CY2018Q3	rtrx	Government Rebates Payable GovernmentRebatesPayable	10377000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1353000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1115000	USD
CY2018Q3	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	rtrx	Provision For Inventory ProvisionForInventory	-1625000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18938000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9314000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13900000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13872000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13500000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13450000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-972000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-749000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36018000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43348000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2018Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7749000	USD
CY2018Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9292000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1015000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1083000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	471800000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	582706000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6960000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21292000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4885000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14920000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	460000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	980000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4506000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4625000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13319000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12996000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11461000	shares
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	201962000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10936000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16318000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16325000	shares
CY2017Q4	us-gaap	Assets Assets	520346000	USD
CY2018Q3	us-gaap	Assets Assets	716186000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	325807000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	502989000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	726000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	808000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	324797000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	201236000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	323993000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	324000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	123272000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	196064000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	77964000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	127929000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-885000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6852000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98991000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99394000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154820000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	57989000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	55426000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1159424	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	79167	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39373745	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41167942	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39373745	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41167942	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17813000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42218000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54447000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95291000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4274000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	800000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2018Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	22377000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	45077000	USD
CY2018Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	192753000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	925000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2431000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1133000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3924000	USD
CY2018Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.077
CY2018Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	8800000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7811000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13336000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13789000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15710000	USD
CY2018Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.10
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.37
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-57000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-30000	USD
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.064
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.110
CY2018Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q3	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2018Q3	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8900000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8901000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8900000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8921000	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	51046000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	64279000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	235863000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	250824000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	184817000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186500000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186545000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1074000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-270000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	29000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-102000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-361000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	5000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	936000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19017000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47325000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54101000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94412000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1223000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5212000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5200000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	425000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6797000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4064000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1346000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	319000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1428000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3747000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2183000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2561000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3094000	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	595000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2460000	USD
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1147000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2905000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-660000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3315000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2533000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4848000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1916000	USD
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1857000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5351000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	5129000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3435000	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3272000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2018Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1300000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227212000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	397121000	USD
CY2017Q3	us-gaap	Legal Fees LegalFees	0	USD
	us-gaap	Legal Fees LegalFees	2000000	USD
CY2018Q3	us-gaap	Legal Fees LegalFees	0	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520346000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	716186000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85668000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	99872000	USD
CY2017Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2000000	USD
CY2018Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2018Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	22600000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	201236000	USD
CY2018Q3	us-gaap	Marketable Securities MarketableSecurities	323993000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4084000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231338000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45705000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-154489000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8257000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21393000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-17794000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42113000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8409000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8711000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18518000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19357000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	50948000	USD
	us-gaap	Operating Expenses OperatingExpenses	151374000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	76289000	USD
	us-gaap	Operating Expenses OperatingExpenses	195530000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10608000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38614000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35583000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-75055000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5556000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7393000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	83000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	256000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	64000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-97000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3902000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5006000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3833000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2472000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4885000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-164000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	15000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	557000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1065000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-90000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-372000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	67552000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	219800000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	219820000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15000000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9632000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15108000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1437000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3112000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3456000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2842000	USD
CY2018Q3	us-gaap	Prepaid Taxes PrepaidTaxes	2141000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	276000000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3645000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	76826000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	96166000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7695000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10379000	USD
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2100000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4300000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3230000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3323000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	17042000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40203000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19610000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58592000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32448000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91762000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	1132000	USD
	us-gaap	Restructuring Charges RestructuringCharges	2611000	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	-242000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	3549000	USD
CY2018Q3	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177655000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262562000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40340000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	112760000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40706000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120475000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24852000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74683000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26107000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77699000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21292000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15114000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4600000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.72
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	319065000	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38654086	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38301893	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40717440	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40149184	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#133f7f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">pantothenate kinase-associated neurodegeneration (“PKAN”). PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">angiotensin receptor blocker (“ARB”), as well as a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Focal segmental glomerulosclerosis ("FSGS")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is a leading cause of end-stage renal disease and nephrotic syndrome (“NS”). There are no U.S. Food and Drug Administration ("FDA") approved pharmacologic treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:bold;">▪</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#2c2c2c;font-weight:normal;">Immunoglobulin A nephropathy ("IgAN")</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, which is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc. ("Censa"), a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria ("PKU"). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin ("BH4") with the potential to provide improved phenylalanine ("Phe") reduction in patients with PKU when compared to BH4.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase ("PAH") enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is party to a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for N-glycanase deficiency ("NGLY1").</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">NGLY1 is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA in 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#424242;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal® (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam® (cholic acid capsules) is approved in the United States (approved and marketed in Europe for select indications as Kolbam) for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola® (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001438533-18-000032-index-headers.html	Edgar Link	pending
0001438533-18-000032-index.html	Edgar Link	pending
0001438533-18-000032.txt	Edgar Link	pending
0001438533-18-000032-xbrl.zip	Edgar Link	pending
ex09302018311.htm	Edgar Link	pending
ex09302018312.htm	Edgar Link	pending
ex09302018321.htm	Edgar Link	pending
ex09312018322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineq318a02.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20180930.xml	Edgar Link	completed
rtrx-20180930.xsd	Edgar Link	pending
rtrx-20180930x10q.htm	Edgar Link	pending
rtrx-20180930_cal.xml	Edgar Link	unprocessable
rtrx-20180930_def.xml	Edgar Link	unprocessable
rtrx-20180930_lab.xml	Edgar Link	unprocessable
rtrx-20180930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2018 Q4 Form 10-Q Financial Statement

#000143853318000032 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2018 Q4 Form 10-Q Financial Statement

#000143853318000032 Filed on November 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx